Vedolizumab patent expiry?

See the DrugPatentWatch profile for Vedolizumab

What date does Vedolizumab's patent expire?

According to DrugPatentWatch.com [1], Vedolizumab, a medication used to treat inflammatory bowel disease (IBD), is manufactured by Takeda Pharmaceuticals. The patent for Vedolizumab in the United States has a complex expiration schedule due to various extensions and re-examinations.

How long does Takeda have exclusivity?

The original patent expiration date for Vedolizumab was in 2022, but it has undergone several extensions and re-examinations. As of my knowledge cutoff, the patent is set to expire in 2033 [1], subject to the usual exclusivity periods granted by the US FDA.

Are there any biosimilars expected before patent expiry?

While biosimilars have been authorized for Vedolizumab in various countries, there has been no official announcement of a US biosimilar approval prior to patent expiry. Companies like Sandoz, a Novartis subsidiary, have developed Vedolizumab biosimilars, but their regulatory progress in the US remains uncertain [2].

What is the process for generic competition after expiry?

After Vedolizumab's patent expires, generic companies can begin developing and marketing their own versions of the medication. This will potentially lead to increased competition, which may lower prices and improve access to the medication for patients. According to the FDA, generic approvals are expected to follow the usual review and approval process [3].

References:

[1] DrugPatentWatch.com (2023): Vedolizumab patent expiration date

[2] Regulatory Focus (2022): Sandoz submits US application for vedolizumab biosimilar

[3] US FDA (2022): Approval process for generic medications